Stock HLUN B H. LUNDBECK A/S
Add to a list
To use this feature you must be a member
Log inSign up

H. Lundbeck A/S Stock

Equities

HLUN B

DK0061804770

Pharmaceuticals

Real-time Estimate Cboe Europe
Other stock markets
 04:20:54 2024-12-05 EST 		5-day change 1st Jan Change
44.03 DKK +0.30% Intraday chart for H. Lundbeck A/S 0.00% +34.19%
12-03 Lundbeck drug met primary endpoint in migraine study FW
12-03 H. Lundbeck A/S Announces Positive Results from the Resolve Trial CI

Valuation: H. Lundbeck A/S

Capitalization 42.03B 5.94B 5.64B 5.24B 4.67B 8.35B 503B 9.22B 64.88B 24.11B 206B 22.29B 21.8B 891B P/E ratio 2024 *
14.2x
P/E ratio 2025 * 12.1x
Enterprise value 51.27B 7.24B 6.88B 6.39B 5.69B 10.19B 613B 11.25B 79.14B 29.41B 252B 27.19B 26.6B 1,087B EV / Sales 2024 *
2.32x
EV / Sales 2025 * 2.02x
Free-Float
30.74%
Yield 2024 *
2.09%
Yield 2025 * 2.41%
More valuation ratios * Estimated data

Chart: H. Lundbeck A/S

Dynamic Chart

Latest news: H. Lundbeck A/S

Lundbeck drug met primary endpoint in migraine study 12-03 FW
H. Lundbeck A/S Announces Positive Results from the Resolve Trial 12-03 CI
JP Morgan raises target price for Lundbeck to DKK 50 (46), reiterates neutral - BN 12-03 FW
H. Lundbeck Completes Acquisition of Longboard Pharmaceuticals 12-02 MT
Lundbeck completes billion dollar acquisition of Longboard Pharmaceuticals 12-02 FW
Lundbeck's acquisition conditions for Longboard have been met, closing the deal on December 2 11-28 FW
H. Lundbeck Closes Tender Offer for Longboard Pharmaceuticals Acquisition 11-28 MT
H. Lundbeck Launches Late-stage Trial of Multiple System Atrophy Drug 11-27 MT
Lundbeck initiates Phase 3 study of amlenetug in multiple system atrophy 11-27 FW
H. Lundbeck Initiates a Phase III Trial with Amlenetug for the Treatment of Multiple System Atrophy 11-27 CI
H. Lundbeck A/S : Lundbeck: possible rebound given outlook 11-20Our Logo
Trump-induced Pharma fears shouldn't be long-lived 11-19Alphavalue
Danske Bank raises target price for Lundbeck to DKK 50 (49), reiterates 'Hold' - BN 11-14 FW
More news

Last Transcript: H. Lundbeck A/S

Logo H. Lundbeck A/S
H. Lundbeck A/S, Q3 2024 Earnings Call, Nov 13, 2024
11-13
More transcripts

Analysts' recommendations: H. Lundbeck A/S

JP Morgan raises target price for Lundbeck to DKK 50 (46), reiterates neutral - BN 12-03 FW
Danske Bank raises target price for Lundbeck to DKK 50 (49), reiterates 'Hold' - BN 11-14 FW
H LUNDBECK : Q3 exceeded expectations; lower end of the guidance upgraded 11-13Alphavalue
Lundbeck expected to report DKK 1,581 million in adjusted ebitda - First Call 11-11 FW
SEB raises target price for Lundbeck to DKK 47 (45), reiterates hold - BN 11-01 FW
More recommendations

Press Releases: H. Lundbeck A/S

Efficacy of Vyepti highlighted by new clinical trial results in severe migraine 12-03 AQ
Lundbeck completes acquisition of Longboard 12-02 AQ
Lundbeck announces expiration of Longboard tender offer and that all tender offer conditions are fulfilled 11-28 AQ
Lundbeck initiates a phase III trial with amlenetug for the treatment of Multiple System Atrophy 11-27 AQ
H Lundbeck A/S : Transcript (Lundbeck Transcript Get Visual 2024 11 13 1300 CET) 11-14 PU
More press releases

News in other languages: H. Lundbeck A/S

H. Lundbeck A/S: Wende in Sicht? 11-22
H. Lundbeck A/S: mogelijk herstel gezien de vooruitzichten 11-21
Lundbeck: possibile rimbalzo in base alle prospettive 11-20
Lundbeck: posible rebote fruto de las perspectivas 11-20
Lundbeck : possible rebond compte tenu des perspectives 11-19
More news

Quotes and Performance

1 day+0.25%
Current month-0.09%
1 month+0.73%
3 months-7.99%
6 months+19.46%
Current year+34.19%
More quotes

Course Extremes

1 week
43.04
Extreme 43.04
44.38
1 month
42.50
Extreme 42.5
46.92
Current year
31.62
Extreme 31.62
49.38
1 year
31.62
Extreme 31.62
49.38
3 years
23.30
Extreme 23.295
49.38
5 years
23.30
Extreme 23.295
49.38
10 years
23.30
Extreme 23.295
49.38
More quotes

Managers and Directors: H. Lundbeck A/S

Director TitleAgeSince
Charl van Zyl CEO
 Chief Executive Officer 57 2023-09-30
Jörg Hornstein DFI
 Director of Finance/CFO 47 2022-08-31
Tarek Samad CTO
 Chief Tech/Sci/R&D Officer - 2021-04-30
Manager TitleAgeSince
Lars Søren Rasmussen CHM
 Chairman 65 2016-03-30
Lene Skole-Sørensen BRD
 Director/Board Member 65 2015-03-24
Lars Erik Holmqvist BRD
 Director/Board Member 65 2015-03-24
More insiders

ETFs: H. Lundbeck A/S

Name Weight AuM 1st Jan change Investor Rating
FIRST TRUST IPOX EUROPE EQUITY OPPORTUNITIES ETF - DISTRIBUTING - USD ETF First Trust IPOX Europe Equity Opportunities ETF - Distributing - USD
0.25% 4 M€ +20.75%
SIMPLIFY DEVELOPED EX-US PLUS DOWNSIDE CONVEXITY ETF - USD ETF Simplify Developed Ex-US Plus Downside Convexity ETF - USD
0.01% 10 M€ -3.35% -
More ETFs: H. Lundbeck A/S

Pharmaceuticals Wholesale

Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi. ($)
H. LUNDBECK A/S Stock H. Lundbeck A/S
+0.30%0.00%+35.26% - 5.94B
MCKESSON CORPORATION Stock McKesson Corporation
-0.96%-2.30%+33.24%+179.88%77.69B
CARDINAL HEALTH, INC. Stock Cardinal Health, Inc.
+1.60%+2.13%+16.55%+166.35%30.31B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD Stock Shanghai Pharmaceuticals Holding Co., Ltd
0.00%-2.64%+19.79%+15.20%9.75B
HUADONG MEDICINE CO., LTD Stock Huadong Medicine Co., Ltd
-2.26%+2.34%-8.54%+6.45%8.95B
SINOPHARM GROUP CO. LTD. Stock Sinopharm Group Co. Ltd.
-2.15%+1.99%+7.89%+21.30%8.4B
EBOS GROUP LIMITED Stock EBOS Group Limited
-1.32%-1.86%+0.21%+3.63%4.33B
GALENICA AG Stock Galenica AG
+0.03%-0.85%+6.07%+21.39%4.29B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD Stock Jointown Pharmaceutical Group Co., Ltd
-2.21%-0.56%-8.47%+2.46%3.58B
CHINA NATIONAL MEDICINES CORPORATION LTD. Stock China National Medicines Corporation Ltd.
-1.35%-3.29%+11.00%+9.62%3.48B
Average -1.01%-0.63%+11.30%+47.37% 15.67B
Weighted average by Cap. -0.84%-1.13%+22.41%+129.68%
See all sector performances

Financials

2024 *2025 *
Net sales 22.06B 3.12B 2.96B 2.75B 2.45B 4.38B 264B 4.84B 34.05B 12.65B 108B 11.7B 11.44B 468B 23.44B 3.31B 3.14B 2.92B 2.6B 4.66B 280B 5.14B 36.18B 13.45B 115B 12.43B 12.16B 497B
Net income 3B 424M 403M 375M 334M 597M 35.94B 659M 4.64B 1.72B 14.74B 1.59B 1.56B 63.71B 3.57B 504M 478M 445M 396M 709M 42.67B 783M 5.51B 2.05B 17.5B 1.89B 1.85B 75.64B
Net Debt 9.24B 1.3B 1.24B 1.15B 1.03B 1.84B 111B 2.03B 14.26B 5.3B 45.33B 4.9B 4.79B 196B 5.39B 761M 723M 672M 599M 1.07B 64.47B 1.18B 8.32B 3.09B 26.45B 2.86B 2.8B 114B
More financial data * Estimated data

Company Profile

Logo H. Lundbeck A/S
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Employees
5,500
Sector
Pharmaceuticals
Calendar
2025-02-04 - Q4 2024 Earnings Release
More about the company

Quotes

Date Price Change Volume
24-12-05 43.96 kr +0.14% 35,182
24-12-04 43.90 kr -0.54% 380,289
24-12-03 44.14 kr +2.08% 409,675
24-12-02 43.24 kr -1.73% 394,048
24-11-29 44.00 kr +0.09% 955,239

Delayed Quote Nasdaq Copenhagen, December 05, 2024 at 04:00 am

More quotes

Income Statement and Estimates

income-statement-evolution-chart H-LUNDBECK-A-S More financial data

Ratings

Trading Rating
Investor Rating
ESG Refinitiv
B-
surperformance-ratings-light-chart H-LUNDBECK-A-SMore Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
43.90DKK
Average target price
50.50DKK
Spread / Average Target
+15.03%
Consensus
Profit revisions
estimates-change-chart H-LUNDBECK-A-S Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart H-LUNDBECK-A-S Company calendar
  1. Stock Market
  2. Equities
  3. HLUN B Stock
United States

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition